Drug Trial Radar · NCT06930352
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Last checked: Nov 21, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jan 15, 2027
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Uma BorateAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kura Oncology, Inc.
- First posted
- Apr 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.
Conditions
- Acute Myeloid Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and/or aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and/or aspiration
CytarabineDrug
Given cytarabine
Echocardiography TestProcedure
Undergo ECHO
HydroxyureaDrug
Given hydroxyurea
LeukapheresisProcedure
Undergo leukapheresis
Multigated Acquisition ScanProcedure
Undergo MUGA
Questionnaire AdministrationOther
Ancillary studies
ZiftomenibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete remission (CR) plus CR/response with hematologic improvementTime frame: After 6 cycles of treatment (cycle length = 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.